MESI-HMNCT07900542
Middle East Study of Infections in Patients With Hematological Malignancies
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Eligibility criteria expanded, about 5 words
- Study description shortened, about 3 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Overall bloodstream infection incidence per 1,000 patient days
Timeframe: 30 days
Secondary (3)
Persistent bloodstream infection
Microbiological relapse
All-cause mortality
Arms and interventions
Bloodstream infection
Bloodstream infection
Other: No Intervention: Observational Cohort
Sites
9 sites in 5 countries
Saudi Arabia 4, United Arab Emirates 2, Jordan 1, Oman 1, Qatar 1